AEGLEA BIOTHERAPEUTICS INC (AGLE)

Company Profile

Aeglea Bio Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2016-04-07. Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The company is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its product candidate is Pegtarviliase, a novel polyethylene glycol modified (PEGylated), human enzyme engineered to reduce elevated levels of total homocysteine circulating in the plasma. The company has engineered pegtarviliase by directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL). The Company’s second product candidate Pegzilarginase is a PEGylated, recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. The company has engineered pegzilarginase with modifications that enhance arginine-degrading activity of the enzyme in human plasma. The firm is engaged in advancing inflammatory bowel disease (IBD) portfolio which consists of SPY001 and SPY002, antibody candidates.

Company Info

AEGLEA BIOTHERAPEUTICS INC

221 Crescent Street, Building 23, Suite 105

Waltham MASSACHUSETTS 78746

P: 16176515940.0

CEO: Anthony G. Quinn

Employees: 18

Website: https://www.aeglea.com/